Literature DB >> 12225791

Vasoactive intestinal peptide (VIP) inhibits the proliferation of bone marrow progenitors through the VPAC1 receptor.

Pranela Rameshwar1, Pedro Gascon, Hyun S Oh, Thomas N Denny, Goafa Zhu, Doina Ganea.   

Abstract

OBJECTIVE: The cellular and molecular mechanisms of hematopoietic stimulation have been studied. However, an understanding of negative effects in the hematopoietic system remains elusive. To this end, we studied the effects of vasoactive intestinal peptide (VIP) on bone marrow (BM) progenitors.
MATERIALS AND METHODS: Different BM cell subsets were used to perform clonogenic assay for granulocytic (CFU-GM) or erythroid (BFU-E and CFU-E) progenitors with 10(-7)-10(-13) M VIP. The relevant receptor was verified with specific antagonists, or agonists, semi-quantitative RT-PCR, and chemical cross-linking studies with stromal membranes.
RESULTS: Assays performed with unfractionated mononuclear cells and enriched CD34(+) cells showed dose-dependent inhibition on BM progenitors with significant inhibition up to 10(-10) M. Nylon wool separated cells, which depleted stroma, reversed the inhibitory effects of VIP between 10 and 20%. Combined experimental evaluation indicated that the effects of VIP on BM functions are mediated through the type 1 receptor (VPAC1). VIP induced the production of TGF-beta and TNF-alpha in BM mononuclear cells and stroma. These cytokines are partly involved in reversing the suppressive effects of VIP on CFU-GM.
CONCLUSIONS: The effect of VIP on BM progenitors could be mediated through direct and indirect mechanism. Direct effects were evident by the suppressive effects of VIP on clonogenic assays with highly purified CD34(+) cells. Indirect effects were mediated through putative functions of the stromal cells and the production of TGF-beta and TNF-alpha.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12225791     DOI: 10.1016/s0301-472x(02)00875-5

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  8 in total

1.  Characterization and use of a rabbit-anti-mouse VPAC1 antibody by flow cytometry.

Authors:  Rebecca J Hermann; Travis Van der Steen; Emilie E Vomhof-Dekrey; Sejaa Al-Badrani; Steve B Wanjara; Jarrett J Failing; Jodie S Haring; Glenn P Dorsam
Journal:  J Immunol Methods       Date:  2011-11-04       Impact factor: 2.303

2.  Constitutive Expression of Inducible Cyclic Adenosine Monophosphate Early Repressor (ICER) in Cycling Quiescent Hematopoietic Cells: Implications for Aging Hematopoietic Stem Cells.

Authors:  Steven J Greco; Ghassan Yehia; Julius A Potian; Carlos A Molina; Pranela Rameshwar
Journal:  Stem Cell Rev Rep       Date:  2017-02       Impact factor: 5.739

3.  Radical reversal of vasoactive intestinal peptide (VIP) receptors during early lymphopoiesis.

Authors:  Emilie E Vomhof-DeKrey; Ashley R Sandy; Jarrett J Failing; Rebecca J Hermann; Scott A Hoselton; Jane M Schuh; Abby J Weldon; Kimberly J Payne; Glenn P Dorsam
Journal:  Peptides       Date:  2011-08-22       Impact factor: 3.750

4.  Vasoactive intestinal peptide signaling axis in human leukemia.

Authors:  Glenn Paul Dorsam; Keith Benton; Jarrett Failing; Sandeep Batra
Journal:  World J Biol Chem       Date:  2011-06-26

Review 5.  A novel mechanism for immunosuppression: from neuropeptides to regulatory T cells.

Authors:  Doina Ganea; Elena Gonzalez-Rey; Mario Delgado
Journal:  J Neuroimmune Pharmacol       Date:  2006-10-10       Impact factor: 4.147

6.  Reactivity of rat bone marrow-derived macrophages to neurotransmitter stimulation in the context of collagen II-induced arthritis.

Authors:  Dominique Muschter; Claudia Göttl; Mandy Vogel; Joachim Grifka; Rainer H Straub; Susanne Grässel
Journal:  Arthritis Res Ther       Date:  2015-06-24       Impact factor: 5.156

7.  VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage.

Authors:  Catalina Abad; Bhavaani Jayaram; Laurine Becquet; Yuqi Wang; M Sue O'Dorisio; James A Waschek; Yossan-Var Tan
Journal:  J Neuroinflammation       Date:  2016-06-29       Impact factor: 8.322

8.  VIPhyb, an antagonist of vasoactive intestinal peptide receptor, enhances cellular antiviral immunity in murine cytomegalovirus infected mice.

Authors:  Jian-Ming Li; Kasia A Darlak; Lauren Southerland; Mohammad S Hossain; David L Jaye; Cassandra D Josephson; Hilary Rosenthal; Edmund K Waller
Journal:  PLoS One       Date:  2013-05-27       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.